About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

HEALIOS K.K.(4593) Summary

4593
TSE Growth
HEALIOS K.K.
237
JPY
+13
(+5.80%)
Apr 10, 2:13 pm JST
1.61
USD
Apr 10, 1:13 am EDT
Result
PTS
outside of trading hours
236.7
Apr 10, 2:09 pm JST
Summary Chart Historical News Financial Result
PER
PBR
11.6
Yield
ー%
Margin Trading Ratio
18.69
Stock Price
Apr 10, 2025
Opening Apr 10, 9:06 am
248 JPY 1.68 USD
Previous Close Apr 9
224 JPY 1.54 USD
High Apr 10, 9:06 am
250 JPY 1.69 USD
Low Apr 10, 9:25 am
230 JPY 1.56 USD
Volume
2,331,600
Trading Value
0.56B JPY 3.79M USD
VWAP
238.55 JPY 1.63 USD
Minimum Trading Value
23,700 JPY 161 USD
Market Cap
0.02T JPY 0.16B USD
Number of Trades
1,542
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
1,132
1-Year High Jan 16, 2025
9,430
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 1,107,200 6,484,500 5.86
Mar 28, 2025 1,995,300 7,697,700 3.86
Mar 21, 2025 2,045,000 7,375,200 3.61
Mar 14, 2025 2,082,900 7,169,900 3.44
Mar 7, 2025 2,196,400 6,605,800 3.01
Company Profile
HEALIOS K.K. develops treatments for intractable diseases using iPS cells. The company collaborates with Sumitomo Pharma and has a business alliance with Nikon.
Sector
Pharmaceuticals
HEALIOS K.K. conducts research and development of regenerative medicine products utilizing iPS cell technology. In the field of somatic stem cell regenerative medicine, the company is advancing the development of HLCM051 for acute cerebral infarction and ARDS (Acute Respiratory Distress Syndrome). In the iPSC regenerative medicine field, which involves transplanting cells with functions similar to the human body created by differentiating iPS cells, HEALIOS K.K. is developing a next-generation platform to create Universal Donor Cells (UDC) with reduced risk of immune rejection. The company's pipeline includes research and development in cancer immunotherapy, age-related macular degeneration treatment, and liver disease treatment. Through joint development with Sumitomo Pharma and collaborations with domestic and international research institutions, HEALIOS K.K. aims to realize new treatments for intractable diseases.